+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

LAMEA Rapid Acting Insulin Market By Product Type, By Indication, By Distribution Channel, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

  • ID: 5322547
  • Report
  • April 2021
  • Region: Middle East, Africa
  • 89 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Adocia SA
  • Biocon Limited
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • MannKind Corporation
  • MORE
The Latin America, Middle East and Africa Rapid Acting Insulin Market is expected to witness market growth of 6.5% CAGR during the forecast period (2021-2027).

By performing rapid-acting insulin opportunity analysis assessment, higher availability of constant glucose tracking will assist in complex analysis of clinic rapid insulin action which was not earlier feasible. This will assist in knowing whether the latest rapid-acting insulin opportunity analysis will offer a superior degree of optimal glycemic control above HbA1c levels, which is needed for regulatory and scientific compliance.

Rapid insulins can both be utilized for bolus doses of insulins. However, many individuals find that rapid-acting insulins are more convenient. Individuals suffering from either type 1 or type 2 diabetes can use rapid-acting insulins. These insulins show rapid action and hence can be taken before the meal. Similarly, it is easy to compare the increase in blood glucose from food absorption to gain the insulin in the blood from the rapid-acting insulin.

The increasing rate of diabetes around the world is expected to create growth avenues for the global rapid insulin market in the next few years. In addition to it, the growth of the market is further propelled by the growing number of research and development (R&D) activities for human recombinant insulin. Moreover, sedentary & unhealthy lifestyle patterns increase the risk of diabetes, as factors like overweight or obesity, an unhealthy diet & physical inactivity are responsible for the majority of diabetes diseases among people.

The Brazil market dominated the LAMEA Insulin Glulisine Market by Country in 2020, growing at a CAGR of 6.3 % during the forecast period. The Argentina market is expected to witness a CAGR of 8% during (2021 - 2027). Additionally, The UAE market is experiencing a CAGR of 7.1% during (2021 - 2027).

The Drug Stores & Retail Pharmacies market dominated the South Africa Rapid Acting Insulin Market by Distribution Channel in 2020, thereby, achieving a market value of $69.2 Million by 2027. The Hospital Pharmacies market is estimated to grow at a CAGR of 7.6% during (2021 - 2027). The Online Providers market is expected to witness a CAGR of 8.1% during (2021 - 2027).

Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine. Based on Indication, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.

Scope of the Study

Market Segments covered in the Report:

By Product Type
  • Insulin Lispro
  • Insulin Aspart
  • Insulin Glulisine
By Indication
  • Type 2 Diabetes
  • Type 1 Diabetes
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers
By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Adocia SA
  • Biocon Limited
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • Wockhardt Ltd.
  • MannKind Corporation
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adocia SA
  • Biocon Limited
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • MannKind Corporation
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Rapid Acting Insulin Market, by Product Type
1.4.2 LAMEA Rapid Acting Insulin Market, by Indication
1.4.3 LAMEA Rapid Acting Insulin Market, by Distribution Channel
1.4.4 LAMEA Rapid Acting Insulin Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)

Chapter 4. LAMEA Rapid Acting Insulin Market by Product Type
4.1 LAMEA Insulin Lispro Market by Country
4.2 LAMEA Insulin Aspart Market by Country
4.3 LAMEA Insulin Glulisine Market by Country

Chapter 5. LAMEA Rapid Acting Insulin Market by Indication
5.1 LAMEA Type 2 Diabetes Market by Country
5.2 LAMEA Type 1 Diabetes Market by Country

Chapter 6. LAMEA Rapid Acting Insulin Market by Distribution Channel
6.1 LAMEA Hospital Pharmacies Market by Country
6.2 LAMEA Drug Stores & Retail Pharmacies Market by Country
6.3 LAMEA Online Providers Market by Country

Chapter 7. LAMEA Rapid Acting Insulin Market by Country
7.1 Brazil Rapid Acting Insulin Market
7.1.1 Brazil Rapid Acting Insulin Market by Product Type
7.1.2 Brazil Rapid Acting Insulin Market by Indication
7.1.3 Brazil Rapid Acting Insulin Market by Distribution Channel
7.2 Argentina Rapid Acting Insulin Market
7.2.1 Argentina Rapid Acting Insulin Market by Product Type
7.2.2 Argentina Rapid Acting Insulin Market by Indication
7.2.3 Argentina Rapid Acting Insulin Market by Distribution Channel
7.3 UAE Rapid Acting Insulin Market
7.3.1 UAE Rapid Acting Insulin Market by Product Type
7.3.2 UAE Rapid Acting Insulin Market by Indication
7.3.3 UAE Rapid Acting Insulin Market by Distribution Channel
7.4 Saudi Arabia Rapid Acting Insulin Market
7.4.1 Saudi Arabia Rapid Acting Insulin Market by Product Type
7.4.2 Saudi Arabia Rapid Acting Insulin Market by Indication
7.4.3 Saudi Arabia Rapid Acting Insulin Market by Distribution Channel
7.5 South Africa Rapid Acting Insulin Market
7.5.1 South Africa Rapid Acting Insulin Market by Product Type
7.5.2 South Africa Rapid Acting Insulin Market by Indication
7.5.3 South Africa Rapid Acting Insulin Market by Distribution Channel
7.6 Nigeria Rapid Acting Insulin Market
7.6.1 Nigeria Rapid Acting Insulin Market by Product Type
7.6.2 Nigeria Rapid Acting Insulin Market by Indication
7.6.3 Nigeria Rapid Acting Insulin Market by Distribution Channel
7.7 Rest of LAMEA Rapid Acting Insulin Market
7.7.1 Rest of LAMEA Rapid Acting Insulin Market by Product Type
7.7.2 Rest of LAMEA Rapid Acting Insulin Market by Indication
7.7.3 Rest of LAMEA Rapid Acting Insulin Market by Distribution Channel

Chapter 8. Company Profiles
8.1 Merck & Co., Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.2 Sanofi S.A.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.2.5.2 Approvals and Trials:
8.3 Novo Nordisk A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental & Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.5.2 Approvals and Trials:
8.3.5.3 Partnerships, Collaborations, and Agreements:
8.4 Eli Lilly and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.4.5.2 Approvals and Trials:
8.4.5.3 Partnerships, Collaborations, and Agreements:
8.5 Adocia SA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expense
8.5.4 Recent strategies and developments:
8.5.4.1 Approvals and Trials:
8.6 Biocon Limited
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Approvals and Trials:
8.7 Gan & Lee Pharmaceuticals
8.7.1 Company Overview
8.7.2 Financial Analysis
8.8 Geropharm LLC
8.8.1 Company Overview
8.9 Wockhardt Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. MannKind Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Acquisition and Mergers:
8.10.4.2 Partnerships, Collaborations, and Agreements:
Note: Product cover images may vary from those shown
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Adocia SA
  • Biocon Limited
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • Wockhardt Ltd.
  • MannKind Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll